Fierce Pharma Asia—BMS’ China asset sale; 2 biotech debuts; 2 potential deals
7.5
来源：
FiercePharma
发布时间：
2025-09-18 15:20
摘要：
BMS is divesting its stake in a historic U.S.-China joint venture, while new biotech firms Kalexo Bio and Ollin Biosciences have launched with significant venture capital backing. Kalexo is developing a dual-target siRNA for cardiovascular diseases, and Ollin focuses on eye diseases. SK Biopharmaceutical's Xcopri shows promising phase 3 trial results, paving the way for FDA expansion. Additionally, Henlius is in discussions with J&J and Roche for a licensing deal on a PD-L1 ADC.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.0
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.0
technical_barrier_competition
0.5
关键证据
BMS is exiting its 60% stake in Sino-American Shanghai Squibb Pharmaceuticals.
Aditum Bio has launched Kalexo Bio with a dual-target siRNA candidate.
SK Biopharmaceutical reported a positive phase 3 readout for Xcopri.
真实性检查
否
AI评分总结
BMS is divesting its stake in a historic U.S.-China joint venture, while new biotech firms Kalexo Bio and Ollin Biosciences have launched with significant venture capital backing. Kalexo is developing a dual-target siRNA for cardiovascular diseases, and Ollin focuses on eye diseases. SK Biopharmaceutical's Xcopri shows promising phase 3 trial results, paving the way for FDA expansion. Additionally, Henlius is in discussions with J&J and Roche for a licensing deal on a PD-L1 ADC.